Iron chelation therapy for patients with sickle cell disease and iron overload

American Journal of Hematology

Volumn 85, Issue 10, 2010, Pages 782-786

  Inati, Adlette ^a,c,d   Khoriaty, Evelyne ^b   Musallam, Khaled M ^b   Taher, Ali T ^b  

^a RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^d Chronic Care Center Hazmieh   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DEFERASIROX; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRITIN; IRON; BENZOIC ACID DERIVATIVE; DEFERIPRONE; IRON CHELATING AGENT; PYRIDONE DERIVATIVE; TRIAZOLE DERIVATIVE; ZINC;

ADULT; ARTICLE; CASE REPORT; CHILD; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERANCE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; INJECTION PAIN; INSOMNIA; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; LACTOSE INTOLERANCE; MALE; NAUSEA; PALLOR; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; REHYDRATION; SCHOOL CHILD; SICKLE CELL ANEMIA; TREATMENT REFUSAL; TREATMENT WITHDRAWAL; VOMITING; ANEMIA, SICKLE CELL; CHELATION THERAPY; CHEMICALLY INDUCED; COMPLICATION; DEFICIENCY; DRUG MONITORING; INFUSION PUMP; METABOLISM; ORAL DRUG ADMINISTRATION; PAIN; PSYCHOLOGY; SENSORY DYSFUNCTION; SOCIAL ISOLATION; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ANEMIA, SICKLE CELL; BENZOATES; CHELATION THERAPY; CHILD; DEFEROXAMINE; DRUG MONITORING; ERYTHROCYTE TRANSFUSION; HUMANS; INFUSION PUMPS; INFUSIONS, SUBCUTANEOUS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; PAIN; PATIENT COMPLIANCE; PYRIDONES; SENSATION DISORDERS; SOCIAL ISOLATION; TRIAZOLES; YOUNG ADULT; ZINC;

EID: 77957687561     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21806     Document Type: Article

References (68)

1. Porter JB. Practical management of iron overload. Br J Haematol 2001;115:239-252.
2. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-573.
3. Modell B, Khan M, Darlison M. Survival in b-thalassaemia major in the UK: Data from the UK Thalassaemia Register. Lancet 2000;355:2051-2052.
4. Cohen A, Schwartz E. Excretion of iron in response to deferoxamine in sickle cell anemia. J Pediatr 1978;92:659-662.
5. Cohen A, Schwartz E. Iron chelation therapy in sickle cell anemia. Am J Hematol 1979;7:69-76.
6. Cohen AR, Mizanin J, Schwartz E. Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy. J Pediatr 1989;115:151-155.
7. Kalpatthi R, Peters B, Holloman D, et al. Safety and efficacy of high dose intravenous desferoxamine for reduction of iron overload due to chronic transfusion in sickle cell patients. Blood 2008;112:abst 1430.
8. Silliman CC, Peterson VM, Mellman DL, et al. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: A randomized, double-blind study of the dose-response relationship. J Lab Clin Med 1993;122:48-54.
9. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986;314:869-873.
10. Leonard MB, Zemel BS, Kawchak DA, et al. Plasma zinc status, growth, and maturation in children with sickle cell disease. J Pediatr 1998;132:467-471.
11. Aydinok Y, Erermis S, Bukusoglu N, et al. Psychosocial implications of thalassemia major. Pediatr Int 2005;47:84-89.
12. Abetz L, Baladi J-F, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life: Results from a literature review. Health Qual Life Outcomes 2006;4:73.
13. Treadwell MJ, Law AW, Sung J, et al. Barriers to adherence of deferoxamine usage in sickle cell disease. Pediatr Blood Cancer 2005;44:500-507.
14. Ferriprox prescribing information. 2007. Available at:http://www. ferriprox.com.
15. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102:17-24.
16. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417-423.
17. Collins AF, Fassos FF, Stobie S, et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 1994;83:2329-2333.
18. Hoffbrand AV, AL Refaie F, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:295-300.
19. Kersten MJ, Lange R, Smeets ME, et al. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): A Dutch multicenter trial. Ann Hematol 1996;73:247-252.
20. Voskaridou E, Douskou M, Terpos E, et al. Deferiprone as an oral iron chelator in sickle cell disease. Ann Hematol 2005;84:434-440.
21. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103:361-364.
22. al Refaie FN, Hershko C, Hoffbrand AV, et al. Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995;91:224-229.
23. Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136:501-508.
24. Cappellini MD, Porter JB, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica 2010;95:557-566.
25. Vichinsky E. Clinical application of deferasirox: Practical patient management. Am J Hematol 2008;83:398-402.
26. Schmid M, Cappellini MD, Porter JB, et al. Safety of deferasirox (Exjade®) in myelodysplastic syndromes (MDS) and non-MDS patients with transfusional iron overload: A pooled analysis focusing on renal function. Blood 2009;114:abst 1768.
27. Vichinsky E, Coates T, Thompson AA, et al. Deferasirox (Exjade®), the once-daily oral iron chelator, demonstrates safety and efficacy in patients with sickle cell disease (SCD): 3.5-year follow-up. Blood 2008;112:abst 1420.
28. Voskaridou E, Douskou M, Plata E, et al. Treatment with deferasirox effectively decreases iron burden in patients with sickle cell syndromes. Haematologica 2009;94(Suppl 2):abst 215.
29. Cancado R, Olivato MC, Bruniera P, Chiattone C. Deferasirox for the treatment of transfusional iron overload in sickle cell anemia: A 1-yr prospective study. Haematologica 2009;94(Suppl 2):abst 210.
30. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11.
31. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353:2769-2778.
32. Wahl S, Quirolo KC. Current issues in blood transfusion for sickle cell disease. Curr Opin Pediatr 2009;21:15-21.
33. Verduzco LA, Nathan DG. Sickle cell disease and stroke. Blood 2009;114:5117-5125.
34. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004;364:1343-1360.
35. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341:1986-1995.
36. Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001;38(Suppl 1):30-36.
37. Darbari DS, Kple-Faget P, Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006;81:858-863.
38. Fung EB, Harmatz P, Milet M, et al. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematol 2007;82:255-265.
39. Voskaridou E, Tsetsos G, Tsoutsias A, et al. Pulmonary hypertension in patients with sickle cell/beta thalassemia: Incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. Haematologica 2007;92:738-743.
40. Mokhtar GM, Adly AA, El Alfy MS, et al. N-terminal natriuretic peptide and ventilation-perfusion lung scan in sickle cell disease and thalassemia patients with pulmonary hypertension. Hemoglobin 2010;34:78-94.
41. Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000;96:76-79.
42. Vichinsky E, Butensky E, Fung E, et al. Comparison of organ dysfunction in transfused patients with SCD or b thalassemia. Am J Hematol 2005;80:70-74.
43. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998;850:227-231.
44. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-30.
45. Inati A, Musallam KM, Wood JC, et al. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. Eur J Haematol 2009;83:565-571.
46. Wood JC, Tyszka JM, Carson S, et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004;103:1934-1936.
47. Fung EB, Harmatz PR, Lee PD, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006;135:574-582.
48. Fillet G, Beguin Y, Baldelli L. Model of reticuloendothelial iron metabolism in humans: Abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood 1989;74:844-851.
49. Walter PB, Fung EB, Killilea DW, et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol 2006;135:254-263.
50. Koren A, Fink D, Admoni O, et al. Non transferrin bound labile plasma iron and iron overload in sickle cell disease: A comparative study between sickle cell disease and beta thalassemic patients. Eur J Haematol 2010;84:72-78.
51. The management of sickle cell disease. NIH Publication No 02-2117. 2002. Available at:http://www.nhlbi.nih.gov/health/prof/blood/sickle/sc-mngt.pdf.
52. Sickle Cell Society. Standards for the clinical care of adults with sickle cell disease in the UK. 2008. Available at:http://www.sicklecellsociety. org/pdf/Care-Book.pdf (last accessed April 2010).
53. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with b-thalassemia. Blood 2006;107:3455-3462.
54. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995;332:918-922.
55. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study. Eur J Haematol 2008;80: 168-176.
56. Porter JB, Huehns ER. Transfusion and exchange transfusion in sickle cell anaemias, with particular reference to iron metabolism. Acta Haematol 1987;78:198-205.
57. Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993;42:81-85.
58. Karam LB, Disco D, Jackson SM, et al. Liver biopsy results in patients with sickle cell disease on chronic transfusions: Poor correlation with ferritin levels. Pediatr Blood Cancer 2008;50:62-65.
59. Pakbaz Z, Fischer R, Gamino R, et al. Serum ferritin a predictor of iron overload in patients with thalassemia and sickle cell disease? Blood 2004;104:abst 3789.
60. Olivieri NF. Progression of iron overload in sickle cell disease. Semin Hematol 2001;38(Suppl 1):57-62.
61. Brown K, Subramony C, May W, et al. Hepatic iron overload in children with sickle cell anemia on chronic transfusion therapy. J Pediatr Hematol Oncol 2009;31:309-312.
62. Pakbaz Z, Fischer R, Fung E, et al. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer 2007;49:329-332.
63. Adamkiewicz TV, Abboud MR, Paley C, et al. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear, and are associated with iron load and liver injury. Blood 2009;114:4632-4638.
64. Inati A, Musallam K, Wood JC, Taher AT. Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease. Blood 2010;115:2980-2981.
65. Inati A, Musallam KM, Cappellini MD, et al. Nontransferrin-bound iron in transfused patients with sickle cell disease. Int J Lab Hematol 2010;[Epub ahead of print] DOI: 10.1111/j.1751-553x.2010.01255.x.
66. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005;18:277-287.
67. Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008;93:741-752.
68. Porter JB, Cappellini MD, El-Beshlawy A, et al. Effect of deferasirox (Exjade®) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large-scale, prospective 1-year EPIC trial. Blood 2008;112:abst 3881.